Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis

Area of Science:

• Neuroscience
• Drug Discovery
• Regenerative Medicine

Background:

• Developing therapeutics for multiple sclerosis (MS) is hindered by challenges in functional screening for remyelination.
• Existing methods for assessing myelination are not suitable for high-throughput screening and cannot resolve cell-autonomous effects.

Purpose of the Study:

• To develop a novel high-throughput screening platform for identifying compounds that promote remyelination.
• To validate the platform's efficacy by screening bioactive molecules and identifying potential therapeutic candidates for MS.

Main Methods:

• Development of a Binary Indicant for Myelination using Micropillar Arrays (BIMA) platform.
• Utilizing engineered micropillars for high-resolution imaging of myelin wrapping.
• Implementing a 96-well plate format for semiautomated acquisition and automated data analysis.

Main Results:

• The BIMA platform enables high-throughput, quantitative assessment of myelination from single 2D images.
• Screening of 1,000 bioactive molecules identified a class of antimuscarinic compounds.
• These compounds demonstrated significant enhancement of oligodendrocyte differentiation and remyelination.

Conclusions:

• The BIMA platform offers a robust solution for high-throughput screening of remyelination-promoting compounds.
• The identified antimuscarinic compounds represent promising leads for developing novel regenerative therapeutics for multiple sclerosis.
• This platform facilitates the discovery of potential treatments for demyelinating diseases.